Thursday, July 9, 2026

pharma · severe uncontrolled asthma · mild to moderate asthma, Chronic Obstructive Pulmonary Disease (COPD) · GENB

Generate Biomedicines

Generate Biomedicines is a pharma organization headquartered in Somerville, USA. It trades on NYSE under ticker GENB. Primary therapeutic focus areas include severe uncontrolled asthma, mild to moderate asthma, Chronic O

Somerville, USA HQ
325 Employees
Public company Type
GENB · NYSE Ticker
Company details
Status
Public
HQ
Somerville, USA
Employees
325
Programs
8
Drugs
7
Patents
1
Clinical program

GB-0895 (SC)

Phase 1 · mab · Asthma

GB-0895 (SC) for Asthma is a Phase 1 program (mab) at Generate Biomedicines with 1 ClinicalTrials.gov record(s).

Internal code GB-0895-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Generate Biomedicines
Phase
Phase 1
Modality
mab
Indication
Asthma
Status
active
Trials
1